CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K

What Happened

• On March 6, 2026, Clover Health Investments, Corp. (CLOV) filed a Form 8-K under Item 7.01 (Regulation FD disclosure) to publish a list of responses to selected supplemental shareholder questions submitted in connection with the company's fourth-quarter 2025 earnings announcement. The supplemental Q&A is furnished as Exhibit 99.1 and is also posted on Clover Health’s investor relations website. The filing is signed by CFO Peter Kuipers.

Key Details

• Date filed: March 6, 2026 (Form 8-K, Item 7.01).
• Subject: Supplemental shareholder Q&A responding to questions from the Q4 2025 earnings announcement.
• Exhibit: 99.1 contains the written Q&A; Exhibit 104 is the embedded Inline XBRL cover page.
• Signed by: Peter Kuipers, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer).

Why It Matters

• The disclosure provides added transparency and direct answers to investor questions about Clover Health’s Q4 2025 results and related topics, and it was shared under Regulation FD to ensure broad, fair distribution. Retail investors can review the Q&A on the company’s investor relations site to get more context around the quarterly results and management’s responses.